Em homens obesos com mais de 45 anos, A incidência de hipogonadismo pode atingir 40%

Em homens obesos
com mais de 45 anos,
A incidência de hipogonadismo
pode atingir 40% 1

1. Dhindsa S, Miller MG, Mcwhirter CL et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010 Jun; 33(6):1186-92.

OLÁ, DOUTOR! BEM VINDO À SUA VISITA

Esse material é um apoio visual destinado exclusivamente a profissionais prescritores e dispensadores de medicamentos. Não compartilhe.

PROGRAMA BAYER PARA VOCÊ

Descontos progressivos durante todo o tratamento do seu paciente

MATERIAL DE APOIO

Saiba mais sobre o relato de um caso de remissão de diabetes tipo 2 em um paciente hipogonádico em tratamento de reposição de testosterona

Referências

  1. Hofstra J, Loves S, van Wageningen B, Ruinemans-Koerts J, Jansen I, de Boer H. High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment. Neth. J. Me. 2008;66(3):103-109.
  2. Biswas M, Hampton D, Newcombe RG, Rees DA. Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life. Clin. Endocrinol. (Oxf). 2012;76(5):665-673.
  3. Hamilton EJ, Gianatti E, Strauss BJ, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin. Endocrinol. (Oxf). 2011;74(3):377-383.
  4. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care. 2004;27(4):861-868.
  5. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. The journal of sexual medicine. 2009;6(5):1232-1247.
  6. Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: current perspectives. Diabetes, metabolic syndrome and obesity : targets and therapy. 2014;7:95-105.
  7. Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int. J. Clin. Pract. 2016;70(3):244-253.
  8. Lopez DS, Qiu X, Advani S, et al. Double trouble: Co-occurrence of testosterone deficiency and body fatness associated with all-cause mortality in US men. Clin Endocrinol (Oxf). 2018 Jan;88(1):58-65.
  9. Dhindsa S, Ghanim H, Batra M, et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. Diabetes Care. 2016 Jan;39(1):82-91.
  10. Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013 Oct 21;169(6):725-33.
  11. Haider A, Haider KS, Saad F. Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy. Endocrinol Diabetes Metab Case Rep. 2017 Sep 4;2017.
  12. Bula Nebido® - Bayer S. A.
  13. Conaglen, H. et al Retrospective Investigation of Testosterone Undecanoate Depot for the Long-term Treatment of Male Hypogonadism in Clinical Practice. J S Med 2014; 11: 574-82

Saiba mais em

Diagnóstico

Os sintomas de hipogonadismo podem variar de acordo com a pessoa.

Terapia

A terapia de reposição de testosterona é caracterizada por uma larga margem de segurança e boa tolerabilidade.

Seus Pacientes

Informações úteis para médicos e seus pacientes.